Revlon Inc. Cl A (REV) Drops 6.21% on January 13

Equities Staff  |

Revlon Inc. Cl A (REV) was one of the Russell 2000's biggest losers for Wednesday January 13 as the stock slid 6.21% to $24.46, a loss of $-1.62 per share. Starting at an opening price of $26.11 a share, the stock traded between $24.46 and $26.11 over the course of the trading day. Volume was 26,212 shares over 218 trades, against an average daily volume of 46,355 shares and a total float of 52.44 million.

The losses send Revlon Inc. Cl A down to a market cap of $1.28 billion. In the last year, Revlon Inc. Cl A has traded between $41.67 and $25.02, and its 50-day SMA is currently $28.08 and 200-day SMA is $33.57.

The stock has a P/E Ratio of 40.8.

Revlon Inc is a cosmetics company. It manufactures, markets and sells cosmetics, women's hair color, beauty tools, fragrances, skincare, anti-perspirants/deodorants and personal care products.

Revlon Inc. Cl A is based out of New York, NY and has some 5,600 employees. Its CEO is Lorenzo Delpani.

For a complete fundamental analysis analysis of Revlon Inc. Cl A, check out’s Stock Valuation Analysis report for REV. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.